Publication:
Fluoxetine induced fecal incontinence in a 9 year old child with autistic spectrum disorder: A case report

dc.contributor.authorsEkinci O., Sabuncuoǧlu O., Berkem M.
dc.date.accessioned2022-03-28T14:56:52Z
dc.date.accessioned2026-01-11T11:43:29Z
dc.date.available2022-03-28T14:56:52Z
dc.date.issued2009
dc.description.abstractDespite the dramatic rise in the use of selective serotonin reuptake inhibitors (SSRIs) in children and adolescents with pervasive developmental disorders (PDD) in recent years, the majority of studies of SSRI use in PDD population demonstrated lower tolerability compared to children without PDD. Among the adverse reactions to SSRI use, gastrointestinal adverse effects (GIS-AE) are common and usually reported to be mild and self limited. Children with PDD are shown to have higher rates of gastrointestinal symptoms including stool inconsistencies than the general childhood population and although not previously shown, they may be more vulnerable to severe GIS-AE of SSRIs. We present a case of a 9 year old girl with PDD not otherwise specified (PDD-NOS) who developed fecal incontinence (FI) in the treatment of fluoxetine which led to the discontinuation of the agent. Clinicians must be aware of severe GIS-AE when using SSRIs in children with PDD.
dc.identifier.issn10177833
dc.identifier.pubmedKPBLA
dc.identifier.urihttps://hdl.handle.net/11424/256399
dc.language.isoeng
dc.relation.ispartofKlinik Psikofarmakoloji Bulteni
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectChild
dc.subjectFecal incontinence
dc.subjectFluoxetine
dc.subjectPervasive developmental disorders (SSRI)
dc.titleFluoxetine induced fecal incontinence in a 9 year old child with autistic spectrum disorder: A case report
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage294
oaire.citation.issue3
oaire.citation.startPage290
oaire.citation.titleKlinik Psikofarmakoloji Bulteni
oaire.citation.volume19

Files